From a clinicopathological perspective, nearly 70 % of Basal-like tumours and just 3 % of Luminal A tumours have a triple negative phenotype (ERα and PR negative and no HER2/neu overexpression) [71], and 65 % of ERα negative/PR positive tumours exhibit a Basal-like PAM50 subtype [63–65]. The gene discussed is ERBB2; the disease is neoplasm.